Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial

Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial

Abstract Notable-HCC (NCT05185531) is a phase 1b trial, aiming to evaluate the safety and preliminary effectiveness of neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT) in early-stage resectable hepatocellular carcinoma (HCC). Twenty patients with HCC of BCLC stage 0-A received 3...

Full description

Bibliographic Details
Main Authors: Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Mingming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Format: Article
Language:English
Published: Nature Portfolio 2024-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-47420-3

Internet

https://doi.org/10.1038/s41467-024-47420-3

Similar Items